Que doit connaître le chirurgien sur l’hidradénite suppurée ?

Sabat, 2020, Hidradenitis suppurativa, Nat Rev Dis Primer, 6, 18, 10.1038/s41572-020-0149-1 Loget, 2018, Misdiagnosis of hidradenitis suppurativa continues to be a major issue. The R-ENS Verneuil study, Ann Dermatol Venereol, 145, 331, 10.1016/j.annder.2018.01.043 Ingram, 2019, British Association of Dermatologists guidelines for the management of hidradenitis suppurativa (acne inversa), Br J Dermatol, 180, 1009, 10.1111/bjd.17537 Jemec, 2012, Clinical practice. Hidradenitis suppurativa, N Engl J Med, 366, 158, 10.1056/NEJMcp1014163 Choi, 2022, Hidradenitis suppurativa in pediatric patients, J Am Acad Dermatol, 86, 140, 10.1016/j.jaad.2020.08.045 Zouboulis, 2015, European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa, J Eur Acad Dermatol Venereol, 29, 619, 10.1111/jdv.12966 Frew, 2020, Hidradenitis suppurativa is an autoinflammatory keratinization disease: a review of the clinical, histologic, and molecular evidence, J Am Acad Dermatol, 1, 62 Prens, 2015, Pathophysiology of hidradenitis suppurativa: an update, J Am Acad Dermatol, 73, S8, 10.1016/j.jaad.2015.07.045 Melnik, 2013, Impaired Notch-MKP-1 signalling in hidradenitis suppurativa: an approach to pathogenesis by evidence from translational biology, Exp Dermatol, 22, 172, 10.1111/exd.12098 Mozeika, 2013, Tumour necrosis factor-alpha and matrix metalloproteinase-2 are expressed strongly in hidradenitis suppurativa, Acta Derm Venereol, 93, 301, 10.2340/00015555-1492 Ring, 2017, Bacterial biofilm in chronic lesions of hidradenitis suppurativa, Br J Dermatol, 176, 993, 10.1111/bjd.15007 Assan, 2020, Anti-Saccharomyces cerevisiae IgG and IgA antibodies are associated with systemic inflammation and advanced disease in hidradenitis suppurativa, J Allergy Clin Immunol, 146, 452, 10.1016/j.jaci.2020.01.045 Bettoli, 2016, Overweight, diabetes and disease duration influence clinical severity in hidradenitis suppurativa-acne inversa: evidence from the national Italian registry, Br J Dermatol, 174, 195, 10.1111/bjd.13864 Malara, 2018, Adipokines are dysregulated in patients with hidradenitis suppurativa, Br J Dermatol, 178, 792, 10.1111/bjd.15904 Revuz, 2008, Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies, J Am Acad Dermatol, 59, 596, 10.1016/j.jaad.2008.06.020 Kelly, 2016, Inflammatory mechanisms in hidradenitis suppurativa, Dermatol Clin, 34, 51, 10.1016/j.det.2015.08.004 Egeberg, 2016, Risk of major adverse cardiovascular events and all-cause mortality in patients with hidradenitis suppurativa, JAMA Dermatol, 152, 429, 10.1001/jamadermatol.2015.6264 Durán-Vian, 2019, High prevalence of non-alcoholic fatty liver disease among hidradenitis suppurativa patients independent of classic metabolic risk factors, J Eur Acad Dermatol Venereol, 33, 2131, 10.1111/jdv.15764 Miller, 2016, Prevalence, risk factors, and comorbidities of hidradenitis suppurativa, Dermatol Clin, 34, 7, 10.1016/j.det.2015.08.002 Crowley, 2014, Association of hidradenitis suppurativa disease severity with increased risk for systemic comorbidities, Br J Dermatol, 171, 1561, 10.1111/bjd.13122 Wertenteil, 2019, Overall and subgroup prevalence of acne vulgaris among patients with hidradenitis suppurativa, J Am Acad Dermatol, 80, 1308, 10.1016/j.jaad.2018.09.040 Garg, 2018, Overall and subgroup prevalence of Crohn disease among patients with hidradenitis suppurativa: a population-based analysis in the United States, JAMA Dermatol, 154, 814, 10.1001/jamadermatol.2018.0878 Schneider-Burrus, 2021, Features associated with quality of life impairment in hidradenitis suppurativa patients, Front Med, 8, 676241, 10.3389/fmed.2021.676241 Schneeweiss, 2020, Risk of inflammatory arthritis after a new diagnosis of hidradenitis suppurativa, JAMA Dermatol, 156, 342, 10.1001/jamadermatol.2019.4590 Schneider-Burrus, 2016, High Prevalence of back pain and axial spondyloarthropathy in patients with hidradenitis suppurativa, Dermatology (Basel), 232, 606, 10.1159/000448838 Egeberg, 2017, Prevalence and risk of inflammatory bowel disease in patients with hidradenitis suppurativa, J Invest Dermatol, 137, 1060, 10.1016/j.jid.2016.11.040 Prens, 2022, New insights in hidradenitis suppurativa from a population-based Dutch cohort: prevalence, smoking behaviour, socioeconomic status and comorbidities, Br J Dermatol, 186, 814, 10.1111/bjd.20954 Vossen, 2018, Hidradenitis Suppurativa: a systematic review integrating inflammatory pathways into a cohesive pathogenic model, Front Immunol, 9, 2965, 10.3389/fimmu.2018.02965 Gasparic, 2017, Recognizing syndromic hidradenitis suppurativa: a review of the literature, J Eur Acad Dermatol Venereol, 31, 1809, 10.1111/jdv.14464 Garg, 2018, Hidradenitis suppurativa is associated with polycystic ovary syndrome: a population-based analysis in the United States, J Invest Dermatol, 138, 1288, 10.1016/j.jid.2018.01.009 Agut-Busquet, 2019, Dowling-Degos disease and hidradenitis suppurativa. epidemiological and clinical study of 15 patients and review of the literature, Acta Derm Venereol, 99, 917, 10.2340/00015555-3225 Gutfilen-Schlesinger, 2021, Should we scan hidradenitis suppurativa patients? A systematic review of radiologic findings, Adv Skin Wound Care, 34, 1, 10.1097/01.ASW.0000753196.64470.6a Scholtes, 2019, Characterization of perianal fistulas in patients with hidradenitis suppurativa, J Eur Acad Dermatol Venereol, 33, e337, 10.1111/jdv.15629 Van der Zee, 2015, New insights into the diagnosis of hidradenitis suppurativa: clinical presentations and phenotypes, J Am Acad Dermatol, 73, S23, 10.1016/j.jaad.2015.07.047 Hurley, 1989 Revuz, 2007, Modifications to the Sartorius score and instructions for evaluating the severity of suppurative hidradenitis, Ann Dermatol Venereol, 134, 173, 10.1016/S0151-9638(07)91613-0 Zouboulis, 2017, Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity, Br J Dermatol, 177, 1401, 10.1111/bjd.15748 Kimball, 2016, HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study, J Eur Acad Dermatol Venereol, 30, 989, 10.1111/jdv.13216 Jalenques, 2020, The prevalence and odds of anxiety and depression in children and adults with hidradenitis suppurativa: Systematic review and meta-analysis, J Am Acad Dermatol, 83, 542, 10.1016/j.jaad.2020.03.041 Garg, 2018, Opioid, alcohol, and cannabis misuse among patients with hidradenitis suppurativa: a population-based analysis in the United States, J Am Acad Dermatol, 79, 495, 10.1016/j.jaad.2018.02.053 Shlyankevich, 2014, Hidradenitis suppurativa is a systemic disease with substantial comorbidity burden: a chart-verified case-control analysis, J Am Acad Dermatol, 71, 1144, 10.1016/j.jaad.2014.09.012 Lapins, 2001, Incidence of cancer among patients with hidradenitis suppurativa, Arch Dermatol, 137, 730 Bertolotti, 2021, Guidelines for the management of hidradenitis suppurativa: recommendations supported by the Centre of Evidence of the French Society of Dermatology, Br J Dermatol, 184, 963, 10.1111/bjd.19710 Jemec, 1998, Topical clindamycin versus systemic tetracycline in the treatment of hidradenitis suppurativa, J Am Acad Dermatol, 39, 971, 10.1016/S0190-9622(98)70272-5 Kimball, 2023, Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials, Lancet, 401, 747, 10.1016/S0140-6736(23)00022-3 Glatt, 2021, Efficacy and safety of bimekizumab in moderate to severe hidradenitis suppurativa: a phase 2, double-blind, placebo-controlled randomized clinical trial, JAMA Dermatol, 157, 1279, 10.1001/jamadermatol.2021.2905 Kofler, 2018, Surgical treatment of hidradenitis suppurativa: an analysis of postoperative outcome, cosmetic results and quality of life in 255 patients, J Eur Acad Dermatol Venereol, 32, 1570, 10.1111/jdv.14892 Van Rappard, 2012, Mild to moderate hidradenitis suppurativa treated with local excision and primary closure, J Eur Acad Dermatol Venereol, 26, 898, 10.1111/j.1468-3083.2011.04203.x Mehdizadeh, 2015, Recurrence of hidradenitis suppurativa after surgical management: a systematic review and meta-analysis, J Am Acad Dermatol, 73, S70, 10.1016/j.jaad.2015.07.044 Orenstein, 2020, Medical and surgical management of hidradenitis suppurativa: a review of international treatment guidelines and implementation in general dermatology practice, Dermatology (Basel), 236, 393, 10.1159/000507323 Deckers, 2017, Inflammatory bowel disease is associated with hidradenitis suppurativa: results from a multicenter cross-sectional study, J Am Acad Dermatol, 76, 49, 10.1016/j.jaad.2016.08.031 Posch, 2017, The role of wide local excision for the treatment of severe hidradenitis suppurativa (Hurley grade III): Retrospective analysis of 74 patients, J Am Acad Dermatol, 77, 123, 10.1016/j.jaad.2017.01.055 Deckers, 2018, Hidradenitis suppurativa treated with wide excision and second intention healing: a meaningful local cure rate after 253 procedures, J Eur Acad Dermatol Venereol, 32, 459, 10.1111/jdv.14770 Van Hattem, 2012, Surgical treatment of sinuses by deroofing in hidradenitis suppurativa, Dermatol Surg, 38, 494, 10.1111/j.1524-4725.2011.02255.x Vaillant, 2022, Outcomes and reliability of perforator flaps in the reconstruction of hidradenitis suppurativa defects: a systemic review and meta-analysis, J Clin Med, 11, 5813, 10.3390/jcm11195813 Ezanno, 2022, The role of negative-pressure wound therapy in the management of axillary hidradenitis suppurativa, Int Wound J, 19, 802, 10.1111/iwj.13678 Harrison, 1987, Recurrence after surgical treatment of hidradenitis suppurativa, Br Med J (Clin Res Ed), 294, 487, 10.1136/bmj.294.6570.487 Ovadja, 2021, Recurrence rates following reconstruction strategies after wide excision of hidradenitis suppurativa: a systematic review and meta-analysis, Dermatol Surg, 47, e106, 10.1097/DSS.0000000000002815 Gibrila, 2019, Radical treatment of hidradenitis suppurativa: comparison of the use of the artificial dermis and pedicled perforator flaps, Ann Chir Plast Esthet, 64, 224, 10.1016/j.anplas.2018.06.013 Bechara, 2021, Efficacy and safety of adalimumab in conjunction with surgery in moderate to severe hidradenitis suppurativa: the SHARPS randomized clinical trial, JAMA Surg, 156, 1001, 10.1001/jamasurg.2021.3655